Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its Series D round will help advance ongoing mid-stage studies.
Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its Series D round will help advance ongoing mid-stage studies.
